Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13 | GenomeWeb

Officials from Tekmira Pharmaceuticals this week updated the company’s research and development efforts, stating that the company continues to expect its lead drug candidate, the cancer therapy TKM-PLK1, to move into phase II testing later this year.

The company is also on track to select another molecule for clinical development before the end of 2013, according to the officials, who made their comments during a conference call held to discuss Tekmira’s first-quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.